Imipenem for treatment of tuberculosis in mice and humans
- PMID: 15980354
- PMCID: PMC1168716
- DOI: 10.1128/AAC.49.7.2816-2821.2005
Imipenem for treatment of tuberculosis in mice and humans
Abstract
Chemotherapy of tuberculosis caused by multiple-drug-resistant (MDR) strains is problematic because of choices limited to relatively inefficacious and toxic drugs. Some beta-lactam antibiotics are active against Mycobacterium tuberculosis in vitro. We investigated the efficacy of imipenem in a mouse model of tuberculosis and in humans with MDR tuberculosis. Mice infected with M. tuberculosis strain H37Rv were treated with isoniazid or imipenem. Residual organisms in lung and spleen and survival of imipenem-treated mice were compared to those of untreated or isoniazid-treated mice. Ten patients with MDR tuberculosis also were treated with imipenem in combination with other first- or second-line agents; elimination of M. tuberculosis from sputum samples was measured by quantitative culture. Although it was less effective than isoniazid, imipenem significantly reduced the numbers of M. tuberculosis organisms in lungs and spleens and improved survival of mice. Eight of 10 patients with numerous risk factors for poor outcomes responded to imipenem combination therapy with conversion of cultures to negative. Seven remained culture-negative off of therapy. There were two deaths, one of which was due to active tuberculosis. Organisms were eliminated from the sputa of responders at a rate of 0.35 log10 CFU/ml/week. Relapse upon withdrawal of imipenem and development of resistance to imipenem in a nonresponder suggest that imipenem exerts antimycobacterial activity in humans infected with M. tuberculosis. Imipenem had antimycobacterial activity both in a mouse model and in humans at high risk for failure of treatment for MDR tuberculosis.
Figures




Similar articles
-
In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.Pharmacology. 2010;85(6):365-71. doi: 10.1159/000299795. Epub 2010 Jun 8. Pharmacology. 2010. PMID: 20530976
-
Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.Int J Infect Dis. 2009 Mar;13(2):170-5. doi: 10.1016/j.ijid.2008.06.001. Epub 2008 Sep 2. Int J Infect Dis. 2009. PMID: 18768342
-
Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso.Ann Afr Med. 2010 Jan-Mar;9(1):15-9. doi: 10.4103/1596-3519.62619. Ann Afr Med. 2010. PMID: 20418644
-
Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.Indian J Med Res. 2015 Sep;142(3):323-9. doi: 10.4103/0971-5916.166599. Indian J Med Res. 2015. PMID: 26458349 Free PMC article.
-
First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11. doi: 10.5588/ijtld.11.0522. Epub 2012 Feb 29. Int J Tuberc Lung Dis. 2012. PMID: 22390880
Cited by
-
Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection.PLoS One. 2021 May 3;16(5):e0249841. doi: 10.1371/journal.pone.0249841. eCollection 2021. PLoS One. 2021. PMID: 33939697 Free PMC article.
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.Am J Respir Crit Care Med. 2022 May 15;205(10):1228-1235. doi: 10.1164/rccm.202108-1976OC. Am J Respir Crit Care Med. 2022. PMID: 35258443 Free PMC article. Clinical Trial.
-
Anti-Tuberculosis Activity of Three Carbapenems, Clofazimine and Nitazoxanide Using a Novel Ex Vivo Phenotypic Drug Susceptibility Model of Human Tuberculosis.Antibiotics (Basel). 2022 Sep 20;11(10):1274. doi: 10.3390/antibiotics11101274. Antibiotics (Basel). 2022. PMID: 36289932 Free PMC article.
-
Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis.Antimicrob Agents Chemother. 2013 Apr;57(4):1941-3. doi: 10.1128/AAC.01957-12. Epub 2013 Jan 18. Antimicrob Agents Chemother. 2013. PMID: 23335736 Free PMC article.
-
Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01319-19. doi: 10.1128/AAC.01319-19. Print 2019 Nov. Antimicrob Agents Chemother. 2019. PMID: 31427291 Free PMC article.
References
-
- Chambers, H. F., T. Kocagoz, T. Sipit, J. Turner, and P. C. Hopewell. 1998. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin. Infect. Dis. 26:874-877. - PubMed
-
- Finch, R. 1986. Beta-lactam antibiotics and mycobacteria. J. Antimicrob. Chemother. 18:6-8. - PubMed
-
- Goble, M., M. D. Iseman, L. A. Madsen, D. Waite, L. Ackerson, and C. R. Horsburgh, Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N. Engl. J. Med. 328:527-532. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical